Telo Genomics Management

Management criteria checks 4/4

Telo Genomics' CEO is Sabine Mai, appointed in Dec 2023, has a tenure of less than a year. directly owns 3.94% of the company’s shares, worth CA$393.46K. The average tenure of the management team and the board of directors is 3.1 years and 4.3 years respectively.

Key information

Sabine Mai

Chief executive officer

CA$30.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	3.9%
Management average tenure	3.1yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO

Sabine Mai

less than a year

Tenure

CA$30,000

Compensation

Dr. Sabine Mai, Ph. D. is CEO at Telo Genomics Corp since 2023 and currently serves as its Interim CEO since 2024 and previously was its Interim CEO since December 2023. She is Chair of Clinical & Scientif...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sabine Mai	Founder	less than a year	CA$30.00k	3.94% CA$ 393.5k
Sherif Louis	President & CTO	5.7yrs	CA$231.51k	2.03% CA$ 203.0k
Christopher Ross	Chief Financial Officer	3.1yrs	CA$67.50k	no data

3.1yrs

Average Tenure

Experienced Management: TELO's management team is considered experienced (3.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sabine Mai	Founder	7.7yrs	CA$30.00k	3.94% CA$ 393.5k
Kenneth Anderson	Member of Clinical & Scientific Advisory Board	7.5yrs	no data	no data
William Meekison	Independent Director	4.3yrs	CA$18.00k	0.042% CA$ 4.2k
Ronald McGlennen	Independent Director	2.3yrs	CA$41.06k	no data
Richard Bender	Member of Clinical Advisory Board	no data	no data	no data
Guido Baechler	Independent Chairman of the Board	5.3yrs	CA$82.12k	no data
Shaji K. Kumar	Member of Clinical Advisory Board	less than a year	no data	no data
David Samuel Siegel	Member of Clinical Advisory Board	less than a year	no data	no data
Hugh A. Rogers	Independent Director	5.7yrs	no data	1.49% CA$ 148.7k
James Berenson	Member of Clinical Advisory Board	less than a year	no data	no data
Hans Knecht	Member of Clinical & Scientific Advisory Board	7.5yrs	no data	no data
Ivan Borrello	Member of Clinical Advisory Board	less than a year	no data	no data

4.3yrs

Average Tenure

58yo

Average Age

Experienced Board: TELO's board of directors are considered experienced (4.3 years average tenure).

Telo Genomics Management

Management criteria checks 4/4

Key information

Recent management updates

High number of new and inexperienced directors

Telo Genomics Corp. Announces Executive Changes

Telo Genomics Corp., Annual General Meeting, Nov 30, 2023

Telo Genomics Corp Announces Chief Executive Officer Changes

Telo Genomics Corp. Appoints Richard A. Bender to Establish and Chair its MM Clinical Advisory Board

Telo Genomics Corp., Annual General Meeting, Dec 01, 2022

Recent updates

High number of new and inexperienced directors

New major risk - Share price stability

Telo Genomics Corp. Announces Executive Changes

New major risk - Market cap size

New major risk - Revenue and earnings growth

New major risk - Financial position

Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone Achieved

Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting

Telo Genomics Corp., Annual General Meeting, Nov 30, 2023

New minor risk - Shareholder dilution

Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding

Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding

Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023

Telo Genomics Corp. announced that it expects to receive CAD 2 million in funding

Telo Genomics' Multiple Myeloma Drug Resistance Study Results Selected for Presentation At the 2023 European Hematology Congress

Telo Genomics Corp Announces Chief Executive Officer Changes

Telo Genomics Corp. Launches A Minimal Residual Disease Clinical Trial in Multiple Myeloma

Telo Genomics Corp. Appoints Richard A. Bender to Establish and Chair its MM Clinical Advisory Board

Telo Genomics Corp., Annual General Meeting, Dec 01, 2022

Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples

Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma

Telo Genomics Corp. Completes the Validation of Suite of Proprietary Automation Tools

Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test

Telo Genomics Corp. Appoints Ron McGlennen as Board of Director

Telo Genomics Corp. Advances Its Lead Product and Implements Automation to Its Workflow

Independent Director exercised options to buy CA$102k worth of stock.

Telo Genomics Corp. announced that it has received CAD 2.28775 million in funding

Telo Genomics Corp. announced that it expects to receive CAD 1.5 million in funding

New 90-day high: CA$0.94

Telo Genomics Appoints Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy

New 90-day high: CA$0.54

Telo Genomics Corp., Annual General Meeting, Mar 04, 2021

New 90-day high: CA$0.27

Telo Genomics Corp. Announces the Positive Results of Its Smoldering Multiple Myeloma Proof of Concept Study

Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’S Disease

Telo Genomics Corp. Announces That Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within Ash 2020 Proceedings

New 90-day low: CA$0.20

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age